Abstract
Since 1975, 191 patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). Complete remission rates were 73% for previously untreated patients, 91% for patients previously treated with radiotherapy and 55% for patients previously treated with chemotherapy. In 59 patients with advanced disease who received no other treatment, a 5-year survival rate of 66% was comparable with that achieved by more toxic mustine-containing combinations. ChlVPP has few side effects, is easily given to outpatients, and can be combined with elective radiotherapy in selected patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Dady, P., McElwain, T., Austin, D. et al. Five years' experience with Ch1VPP: Effective low-toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 45, 851–859 (1982). https://doi.org/10.1038/bjc.1982.137
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.137
This article is cited by
-
VIM-D salvage chemotherapy in Hodgkin's disease
Cancer Chemotherapy and Pharmacology (1990)
